{"filing":{"accession_number":"0001493152-26-032925","cik":"0001430306","ticker":"TNXP","company_name":"Tonix Pharmaceuticals Holding Corp.","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1430306/000149315226032925/form8-k.htm"},"events":[{"id":17457,"run_id":15631,"accession_number":"0001493152-26-032925","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The filing discloses a major managed Medicare payer agreement for TONMYA® effective January 1, 2027, adding approximately 9 million Medicare lives (16% of U.S. Medicare beneficiaries). Combined with prior commercial coverage agreements and Medicaid availability, this brings total pharmacy coverage to approximately 145 million covered lives (46% of all covered lives). The company is also expanding its sales force by 50 representatives. This is a material operational and commercial milestone for the company's flagship product launch, but does not fit the specific categories of M\u0026A activity, earnings release, or other defined event types—it is a significant business development and market access achievement.","company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":15937,"accession_number":"0001493152-26-032925","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a major managed Medicare payer agreement for TONMYA® effective January 1, 2027, adding approximately 9 million Medicare lives (16% of U.S. Medicare beneficiaries). Combined with prior commercial coverage agreements and Medicaid availability, this brings total pharmacy coverage to approximately 145 million covered lives (46% of all covered lives). The company is also expanding its sales force by 50 representatives. This is a material operational and commercial milestone for the company's flagship product launch, but does not fit the specific categories of M\u0026A activity, earnings release, or other defined event types—it is a significant business development and market access achievement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T11:13:07.292905+00:00","company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","filing_date":"2026-07-13"}]}